Lipid nanoparticles (LNPs) have emerged as a promising platform for delivering therapeutic payloads, particularly mRNA and gene-editing technologies, to the central nervous system (CNS). LNPs offer several advantages over traditional viral vectors, including improved safety profiles, scalable manufacturing, and versatility in payload encapsulation[1].
LNPs are typically composed of four key components:
The blood-brain barrier (BBB) presents a significant challenge for CNS drug delivery. LNPs can be engineered to cross the BBB through several mechanisms:
Once across the BBB, LNPs are internalized by target cells through endocytosis. The ionizable lipid component facilitates endosomal escape, releasing the therapeutic payload into the cytoplasm where it can exert its effect[4].
| Feature | LNP | AAV |
|---|---|---|
| Payload capacity | ~10 kb | ~4.7 kb |
| Manufacturing scale | Scalable, cost-effective | Complex, limited scale |
| Immune response | Lower pre-existing immunity | Significant pre-existing immunity |
| Repeat dosing | Feasible | Limited by immune response |
| CNS targeting | Requires optimization | Natural CNS tropism |
LNPs can deliver:
Recent studies have advanced LNP-mediated CNS delivery:
While no LNP-based CNS therapies are currently approved, several clinical trials are underway:
LNPs have demonstrated a favorable safety profile in clinical settings:
Mitchell MJ, et al. Engineering LNP for CNS delivery. Nat Rev Drug Discov. 2024. ↩︎
Son S, et al. Ionizable lipid design for mRNA delivery. J Control Release. 2024. ↩︎
Jiang Y, et al. BBB-crossing LNP through receptor-mediated transcytosis. Sci Transl Med. 2024. ↩︎
Liu S, et al. Endosomal escape mechanisms for LNP delivery. Mol Ther. 2025. ↩︎
Chen X, et al. Brain-targeted LNP optimization. Adv Mater. 2025. ↩︎
Wilson JM, et al. Microglial targeting with CD47-LNP. Nat Neurosci. 2025. ↩︎
Brown A, et al. Engineering AAV-like tropism in LNP. 2026. ↩︎